Ezetimibe Side Effects
Links shared publicly online about this topic
RxEconsult, LLC - Vytorin (ezetimibe/simvastatin) for cholesterol reduction
rxeconsult.com — “RxEconsult, LLC - Vytorin (ezetimibe/simvastatin) for cholesterol reduction” View full resource at rxeconsult.com
Most Recently Shared on September 20, 2011 at 11:58 am By:
RxEconsult. If you are in need of healthcare services or information, please visit RxEconsult.
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Dr. Ogbru has written several journal articles. In 1997, he shared an award from the American Journal of Pain Management for Outstanding Contribution to the Interdisciplinary Pain Management Literature. Over the last 12 years Dr. Ogbru has held several roles in the pharmaceutical industry, including Director of Global Medical Information and Communication." /> Ome Ogbru, PharmD Active Health Library, Doctor, Pharmacist, and PharmD
Combined Effects of Ezetimibe and Phytosterols on Cholesterol Metabolism
circ.ahajournals.org — “Combined Effects of Ezetimibe and Phytosterols on Cholesterol Metabolism” View full resource at circ.ahajournals.org
Most Recently Shared on July 24, 2011 at 10:49 am By:
James Underberg Internist, Physician, and Doctor
Combined Effects of #Ezetimibe & #Phytosterols on #Cholesterol Metabolism in Humans cholesterol benefits but CV ? http://bit.ly/o4yDui #fb
Ezetimibe/Simvastatin Is More Effective Than Atorvastatin In Metabolic Syndrome
medicalnewstoday.com — “New data indicate that patients with metabolic syndrome have a greater likelihood of reaching specified lipid and high-sensitivity C-reactive protein (hs-CRP) levels if they are treated with ezet” View full resource at medicalnewstoday.com
Most Recently Shared on September 29, 2010 at 6:05 pm By:
Ezetimibe/Simvastatin Is More Effective Than Atorvastatin In Metabolic Syndrome http://mnt.to/3Kxr #healthnews
Benefits And Side Effects Of Statins
medicalnewstoday.com — “A March 19 article in Time Magazine about the use of statins in women and a recent statement from the U.S. Food and Drug Administration (FDA) about the use of simvastatin in men and women h” View full resource at medicalnewstoday.com
Most Recently Shared on March 24, 2010 at 7:37 am By:
Benefits And Side Effects Of Statins A March 19 article in Time Magazine about the use of statins in women and a rece.. http://bit.ly/cSrJrS
The effects of ezetimibe vs. niacin on measures of mean carotid IMT in HALTS trial
endocrinetoday.com — “American Heart Association Scientific Sessions 2009 In today’s online issue of the New England Journal of Medicine, Taylor et al described” View full resource at endocrinetoday.com
Most Recently Shared on November 16, 2009 at 3:51 pm By:
In-depth analysis of the ARBITER 6-HALTS trial http://ow.ly/CL0e #AHA09
Can I Stop Taking Vytorin Without Bad Side Effects? - Health Advice (usnews.com)
health.usnews.com — “Yes, many physicians have switched patients without harm.” View full resource at health.usnews.com
Most Recently Shared on January 14, 2010 at 10:17 pm By:
HealthIT Policy Health News and Health IT
Can I Stop Taking Vytorin Without Bad Side Effects?: Yes, many physicians have switched patients without harm. http://bit.ly/8qvsYY
Zocor Side Effects
lawyersandsettlements.com — “Zocor Side Effects” View full resource at lawyersandsettlements.com
Most Recently Shared on July 4, 2011 at 1:48 am By:
Zocor Side Effects: http://t.co/2Hz2HJd via @addthis
Full ARBITER 6-HALTS results for niacin/ezetimibe study
theheart.org — “The final results of ARBITER 6-HALTS, which include an additional 107 patients who completed the closeout assessment after a mean of seven months of treatment, are line with the preliminary results showing that niacin added to statin therapy resulted in a significant regression of carotid IMT, whereas treatment with ezetimibe did not.” View full resource at theheart.org
Most Recently Shared on April 15, 2010 at 7:46 am By:
James Rudd Internist, Cardiologist, Physician, and Doctor
ARBITER 6-HALTS: Final results from complete study population published http://j.mp/9vV9CR
Full ARBITER 6-HALTS results for niacin/ezetimibe study
theheart.org — “The final results of ARBITER 6-HALTS, which include an additional 107 patients who completed the closeout assessment after a mean of seven months of treatment, are line with the preliminary results showing that niacin added to statin therapy resulted in a significant regression of carotid IMT, whereas treatment with ezetimibe did not.” View full resource at theheart.org
Most Recently Shared on April 14, 2010 at 9:25 pm By:
ARBITER 6-HALTS: Final results from complete study population published: The final results of ARBITER 6-HALT... http://bit.ly/9R2x2l #ACC10
Side Effects of Lipitor
hearthealthyonline.com — “Know the possible long-term effects of cholesterol-lowering medication” View full resource at hearthealthyonline.com
Most Recently Shared on April 12, 2010 at 7:49 pm By:
Susan Scroggins Active Health Library and Health Advocate
Side effects of Lipitor: What you should look out for when starting this cholesterol-lowering medication. http://bit.ly/aiy8I7
Benefits And Side Effects Of Statins
mnt.to — “A March 19 article in Time Magazine about the use of statins in women and a recent statement from the U.S. Food and Drug Administration (FDA) about the use of simvastatin in men and women h” View full resource at mnt.to
Most Recently Shared on March 24, 2010 at 7:21 am By:
MedicalNewsToday: Benefits And Side Effects Of Statins http://bit.ly/bh0RB6 Full http://bit.ly/cCUR2K
Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis - Full Text View - ClinicalTrials.gov
clinicaltrials.gov — “Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis - Full Text View - ClinicalTrials.gov” View full resource at clinicaltrials.gov
Most Recently Shared on July 13, 2009 at 1:28 pm By:
M Auron MD Doctor, Pediatrician, Internist, and Physician
Esetimibe vs niacin trial stopped, but not for safety reasons -will the cheap niacin be superior??? - http://bit.ly/xeRkx
Endocrinology News - Lipid-lowering and anti-inflammatory effect of ezetimibe in hyperlipidemic patients with coronary artery disease |3986406
mdlinx.com — “Endocrinology Medical Article: Lipid-lowering and anti-inflammatory effect of ezetimibe in hyperlipidemic patients with coronary artery disease” View full resource at mdlinx.com
Most Recently Shared on March 23, 2012 at 5:51 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Lipid-lowering and anti-inflammatory effect of ezetimibe in hyperlipidemic patients with coronary artery d... http://t.co/n5tLlTye #endo
Understanding Medication Side Effects - Medbroadcast
medbroadcast.com — “Serious side effects from cholesterol medication are rare. But it's important to understand why side effects occur, how they can be related to your medication dose, and what to do about side effects.” View full resource at medbroadcast.com
Most Recently Shared on January 21, 2011 at 2:37 pm By:
Understanding medication side effects: http://bit.ly/fj3xUq
Cholesterol drug side effects need watching: study | Reuters
reuters.com — “LONDON (Reuters) - People using cholesterol-lowering statins have a higher risks of liver dysfunction, kidney failure, muscle weakness and cataracts and such side effects of the drug should be closely” View full resource at reuters.com
Most Recently Shared on May 21, 2010 at 12:57 am By:
Cholesterol drug side effects need watching: study http://link.reuters.com/xej55k
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
RxEconsult. If you are in need of healthcare services or information, please visit RxEconsult.
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Dr. Ogbru has written several journal articles. In 1997, he shared an award from the American Journal of Pain Management for Outstanding Contribution to the Interdisciplinary Pain Management Literature. Over the last 12 years Dr. Ogbru has held several roles in the pharmaceutical industry, including Director of Global Medical Information and Communication." />Ome Ogbru, PharmD
Dr. Ome Ogbru is the founder of RxEconsult, which is a social network for healthcare consulting, healthcare jobs, healthcare professionals, healthcare small businesses, life scientists, health information, and more. Members have profiles with details about their services on RxEconsult. If you are in need of healthcare services or information, please visit RxEconsult.
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Dr. Ogbru has written several journal articles. In 1997, he shared an award from the American Journal of Pain Management for Outstanding Contribution to the Interdisciplinary Pain Management Literature. Over the last 12 years Dr. Ogbru has held several roles in the pharmaceutical industry, including Director of Global Medical Information and Communication. -
James Underberg
International expert in CVD prevention, cholesterol & hypertensive disorders. Consider Supporting me for AHA Heart Run http://to.ly/9P7Y
-
MNT Health News
Featured health news published by Medical News Today and chosen by the editorial team.
Advertisement
